
France · Research startup
Genomines is a deeptech and biotechnology startup based in Paris, France, with operations in Saclay.
Funding reportedLast round: Grant
Genomines is a deeptech and biotechnology startup based in Paris, France, with operations in Saclay.
Founded in 2021, the company focuses on transforming the metal extraction industry through sustainable practices. Genomines aims to replace traditional mining methods with plant-based metal farming, also known as agromining, which is both regenerative and carbon-neutral. The company utilizes genetically enhanced hyperaccumulator plants to extract metals from low-concentration soils, significantly improving efficiency compared to native plants. Genomines' primary product is battery-grade nickel, essential for electric vehicle batteries, but its technology also supports the extraction of other critical materials like cobalt and rare earth elements. In addition to metal extraction, Genomines offers services in soil remediation and industrial deployment support, contributing to cleaner supply chains for governments and corporations. With a vision to become the world's first carbon-neutral mining group, Genomines is committed to sustainable practices that benefit both the environment and local communities.
Funding, as reported
From Genomines's own website: 24 on the team.
And 6 more on the team.
What they build
Known for
biomass metal recoverybiotechnologiesbiotechnology researchplant-based metal extraction from tailingshyperaccumulatorsplant microbiome enhancementsoil metal identificationplant biotechnologymetal recovery from plantsenvironmental impact reductionplant root bioaccumulationenvironmental servicesphytoremediationpolluted land remediationsustainable extractionplant biotechnology for metals
Built with from their website
OneTrust Tech Risk & CompliancePWAGoogle CloudFlowGoogle WorkspaceViewport MetaSAP Crystal SolutionsGoogle Cloud HostingGoogle MeetAct!
Mobile FriendlyVercelOpen GraphApple iOSMag+Advanced Solutions InternationalCisco SpacesEaglestats
Add your raise, your deck and your story, and put Genomines in front of investors. Or tell us what we have wrong.